Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Clinical trial NCT05137860 · UNKNOWN

Trial details

NCT number: NCT05137860
Sponsor: Hospital General de Mexico
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukemia, in Relapse Chemotherapeutic Toxicity Minimal Residual Disease

Start date: 2021-12-12
Primary completion: 2022-12-22
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.